0000000000335669

AUTHOR

Paul-egbert Reimitz

showing 3 related works from this author

Meta-analysis of blood pressure (BP) reductions with olmesartan medoxomil (OM) compared with active control (AC) in patients (pts) with hypertension …

2015

Meta-analysis of blood pressure (BP) reductions with olmesartan medoxomil (OM) compared with active control (AC) in patients (pts) with hypertension (HTN) Josep Redon,y, 6 Prakash Deedwania, Kazuomi Kario, Jiguang Wang, Joris Versteden, Paul-Egbert Reimitz. Daiichi Sankyo Europe GmbH, Munich, Germany; Daiichi Sankyo Europe GmbH, Munich, Germany; Jichi University School of Medicine, Japan; Shanghai Institute of Hypertension, Shanghai, China; University of California San Francisco, San Francisco, CA, United States; University of Valencia, Madrid, Spain

medicine.medical_specialtybusiness.industryActive controlEndocrinologyBlood pressureInternal medicineMeta-analysisInternal MedicinemedicineIn patientCardiology and Cardiovascular MedicinebusinessOlmesartanmedicine.drugJournal of the American Society of Hypertension
researchProduct

Meta-analysis of olmesartan medoxomil (OM) monotherapy in reducing blood pressure (BP) in elderly patients with hypertension (HTN)

2015

Meta-analysis of blood pressure (BP) reductions with olmesartan medoxomil (OM) compared with active control (AC) in patients (pts) with hypertension (HTN) Josep Redon,y, 6 Prakash Deedwania, Kazuomi Kario, Jiguang Wang, Joris Versteden, Paul-Egbert Reimitz. Daiichi Sankyo Europe GmbH, Munich, Germany; Daiichi Sankyo Europe GmbH, Munich, Germany; Jichi University School of Medicine, Japan; Shanghai Institute of Hypertension, Shanghai, China; University of California San Francisco, San Francisco, CA, United States; University of Valencia, Madrid, Spain

medicine.medical_specialtyBlood pressurebusiness.industryInternal medicineMeta-analysisInternal MedicinemedicineIn patientCardiology and Cardiovascular MedicinebusinessOlmesartanActive controlmedicine.drugJournal of the American Society of Hypertension
researchProduct

Comparative effectiveness of an angiotensin receptor blocker, olmesartan medoxomil, in older hypertensive patients

2018

The efficacy and safety of olmesartan medoxomil (OM) vs active control (AC) monotherapy among elderly patients aged 60‐79 years (N = 4487) was evaluated by meta‐analysis (25 studies). In all patients, change from baseline to end point in blood pressure (BP) was significantly greater with OM vs AC (−19.5/−11.9 vs −16.8/−10.7 mm Hg). Greater proportions of OM‐ vs AC‐treated patients achieved BP goals. In patients with impaired renal function (estimated glomerular filtration rate <60 mL/min/1.73 m(2)), OM treatment resulted in a greater mean change from baseline in systolic BP vs AC (−21.2 vs −18.7 mm Hg, respectively) and a greater proportion of patients achieving BP goals. These parameters w…

medicine.medical_specialtyAngiotensin receptorEndocrinology Diabetes and MetabolismUrologyRenal functionBlood Pressure030204 cardiovascular system & hematologyHypertension Therapy03 medical and health sciencesImpaired renal functionAngiotensin Receptor Antagonists0302 clinical medicineDiabetes mellitusInternal MedicinemedicineHumansIn patient030212 general & internal medicineAdverse effectAgedOlmesartan Medoxomilbusiness.industryMiddle Agedmedicine.diseaseBlood pressureTreatment OutcomeHypertensionCardiology and Cardiovascular MedicineOlmesartanbusinessmedicine.drug
researchProduct